Home / Themes / MedTech Long '26: Diagnostics & Early Detection
MedTech Long '26: Diagnostics & Early Detection Portfolio (view performance)
Last updated
Theme thesis · 5/5 sections · Tickers 9 with notes · 7 pending
Bull / Bear Details has the investment thesis and bull/bear points. Overview is monitoring guidance (hiring, forums, second-order trends, search keywords, Google Trends, datasets).
Bull / Bear DetailsThe Diagnostics & Early Detection theme remains bullish, driven by accelerating AI and genomic advancements, robust demand from an aging population, and support
Thesis
The Diagnostics & Early Detection theme remains bullish, driven by accelerating AI and genomic advancements, robust demand from an aging population, and supportive regulatory tailwinds for multi-cancer detection. Despite persistent reimbursement and commercialization challenges, the sector demonstrates strong growth and market penetration.
Bull case
Accelerating technological advancements in genomics, AI, and multiomics are driving the development and adoption of highly effective diagnostic and early detection technologies, expanding clinical utility and market opportunities, as evidenced by Tempus AI's AI-powered platform and Guardant Health's InfinityAI.
The increasing global prevalence of chronic diseases, particularly cancer, combined with an aging population, creates a sustained and growing demand for advanced diagnostic solutions and proactive health monitoring, fueling the need for early detection tests like Guardant Health's Shield.
Favorable regulatory developments and legislative actions, including the MCED Act establishing Medicare coverage pathways for multi-cancer early detection tests and ongoing FDA submissions for novel assays, are enhancing market access and accelerating commercialization.
Bear case
Persistent reimbursement pressures and evolving payer policies, including potential average selling price (ASP) declines due to changing patient mix or delayed coverage for novel tests like MRD, could significantly impact profitability and market uptake across the sector.
Significant regulatory hurdles, lengthy approval processes, and the requirement for extensive evidence generation, particularly for novel multi-cancer early detection (MCED) tests, can impede timely rollout and broad adoption, as seen with ongoing challenges in the MCED field.
Intensifying competition from both established players and new entrants in the diagnostics and early detection space may lead to pricing pressures, increased commercialization costs, and potential margin compression across the sector, particularly for high-growth segments like liquid biopsy.
Overview
Hiring Trend Watchpoints
Forum Watchlist
- Reddit — r/oncologyHigh
Clinical trial discussions, new research, physician perspectives on diagnostic utility, reimbursement debates, real-world evidence
- Reddit — r/medtechMedium
Industry trends, device innovation, regulatory impact, M&A speculation, market access challenges
- Reddit — r/liquidbiopsyHigh
Specific technology advancements, clinical utility debates, adoption barriers, competitive landscape
- X/Twitter — #MCEDHigh
Real-time news, policy developments (e.g., MCED Act), clinical data releases, public perception
- LinkedIn — Molecular Diagnostics Professionals GroupMedium
Professional insights, hiring trends, partnership announcements, regulatory updates
Second Order Trends
Search Keywords Brand Product
- Cologuard
- Cancerguard
- Oncodetect
- Signatera
- CLARITY
- Guardant360
- Guardant Reveal
- Shield test
- RaDaR MRD
- TissueCypher
- Galleri test
- NeXT Personal
- Infinity AI
- Smart Platform
- GuardantOMNI
- Tempus xT
- Tempus xR
- Tempus xF
- Tempus MRD
- Paige Predict
- Reveal Ultra
- Guardant360 CDx
- Guardant INFORM
- GuardantConnect
- Tempus xH
- Tempus xE
- Tempus nP assay
Search Keywords Policy Regulatory
- Medicare coverage diagnostics
- ADLT status
- FDA approval diagnostics
- clinical guidelines cancer
- NCCN guidelines
- ACS guidelines
- multi-cancer early detection legislation
- LDT regulation
- MCED Act
- MolDx coverage
- CMS reimbursement diagnostics
- Payer coverage liquid biopsy
Search Keywords Event Phrases
- Q2 2026 earnings
- ASCO 2027
- AACR 2027
- product launch diagnostics
- partnership announcement medtech
- acquisition news diagnostics
- Guardant Health Q2
- Tempus AI Q2
- FDA approval xF liquid biopsy
- Galleri FDA approval
- NovaSeq X transition
- MolDx Reveal coverage
Google Trend Product Category Intent
Google Trend Consumer Intent
Google Trend Macro Policy Terms
Top datasets to track
1. FDA Diagnostic Device Approvals Type: Regulatory Data · Provider: FDA Cadence: Monthly/Quarterly Why it matters: Tracks potential delays or acceleration in the approval process for new diagnostic technologies, directly impacting market entry and revenue generation, especially for novel liquid biopsies and MCED tests. Suggested query: FDA 510(k) clearances diagnostics, PMA approvals oncology, Guardant360 Liquid FDA, Tempus xF FDA approval, Galleri FDA approval Confidence: 0.95
2. NIH Genomics Research Funding Type: Funding Data · Provider: NIH Cadence: Quarterly Why it matters: Indicates investment and focus on genomics technologies, signaling long-term innovation and potential for new diagnostic breakthroughs, particularly in multiomics and AI-driven diagnostics. Suggested query: NIH grants genomics, NCI funding liquid biopsy, AI in diagnostics research funding, multiomics research grants Confidence: 0.85
3. Diagnostic Test Volume & Sales (Alternative Data) Type: Alternative Data (Transactional) · Provider: Earnest Analytics / Similarweb Cadence: Monthly Why it matters: Reflects real-world demand trends for diagnostics and monitoring devices, providing early signals on adoption rates and market share shifts for key products like Shield, Cologuard, and MRD tests. Suggested query: Guardant Shield test volumes, Cologuard sales trends, Signatera test volumes, Tempus MRD test orders, liquid biopsy market share Confidence: 0.9
4. Diagnostic Sales Force Expansion (Hiring Data) Type: Alternative Data (Hiring) · Provider: Thinknum / LinkUp Cadence: Monthly Why it matters: Gauges the pace of commercial build-out for new products (e.g., Shield) and overall market expansion efforts, indicating management's confidence in growth and market penetration strategies. Suggested query: Guardant Health sales jobs, Natera commercial roles, Tempus AI sales force, Exact Sciences hiring, diagnostic sales representative job postings Confidence: 0.85
5. Diagnostic Reimbursement Policy Changes Type: Policy Data · Provider: CMS, Private Payer Websites, Industry News Cadence: As available (ad-hoc) Why it matters: Directly impacts the profitability and market access for diagnostic tests. Favorable policy changes (e.g., ADLT status, new Medicare coverage under MCED Act) are strong bullish signals. Suggested query: Medicare coverage MCED tests, MolDx coverage Reveal, ADLT status liquid biopsy, CMS diagnostic reimbursement updates, private payer coverage cancer screening Confidence: 0.95
Key Metrics
No data for this section.
Upcoming Catalysts
| Catalyst | Estimated Timing | Estimated Date Start | Estimated Date End | Why It Matters | Ticker Or Theme Specific | Source Types | Contributing Tickers | Mention Count | Base Score | Source Weight | Specificity Weight | Macro Bridge | Macro Bridge Multiplier | Theme Score | Date Aggregated | Manual Override | Bridge Mention Count | Theme Base Score | Theme Importance Score | Catalyst Source | Catalyst ID | Transcript Date | Source Type |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Guardant Health (GH) securing additional MolDx/Medicare reimbursement for its Reveal molecular residual disease (MRD) test in new indications, such as breast cancer MRD or immuno-oncology/chemotherapy monitoring. | H2 2026 - H1 2027 | 2026-07-01 | 2027-06-30 | Securing additional Medicare reimbursement for Guardant Health's Reveal in new indications would significantly expand the clinical utility and addressable market for this fast-growing oncology product, demonstrating continued regulatory support for advanced diagnostic solutions. | Theme | theme_composer | GH, NTRA, NEO | 3 | 0.0001 | 1.18 | 0.92 | Regulatory/Policy | 1.35 | 0.0208 | 2026-07-18 | False | 2 | 0.4011 | 58.7819 | Theme composer | |||
| Ramp-up of Guardant Health (GH) Shield test volumes through strategic collaborations with Quest Diagnostics and PathGroup, and broader commercial payer adoption. | Throughout 2026 - H1 2027 | 2026-07-01 | 2027-06-30 | These strategic collaborations and increasing commercial payer coverage are crucial for Guardant Health to expand the national reach and commercial infrastructure for its Shield colorectal cancer screening test, directly driving significant volume growth and revenue for a key early detection product. | Ticker | theme_composer | GH, LH, DGX | 3 | 0.0001 | 1.18 | 0.92 | 1.0 | 0.0131 | 2026-07-18 | False | 1 | 0.401 | 43.5335 | Theme composer | ||||
| Tempus AI (TEM) FDA approval for its xF liquid biopsy. | H2 2026 - H2 2027 | 2026-07-01 | 2027-12-31 | FDA approval for Tempus AI's xF liquid biopsy would expand its diagnostic portfolio, potentially driving significant revenue growth and contributing to an improved average selling price (ASP) for its advanced genomic tests, enhancing its competitive position. | Theme | theme_composer | TEM | 2 | 0.0 | 1.18 | 0.85 | Regulatory/Policy | 1.35 | 0.0024 | 2026-07-18 | False | 2 | 0.2002 | 27.1035 | Theme composer | |||
| Transition from limited market release to full market release of the Bolt 2.0 PFA catheter in the US. | in the third quarter | 2026-07-01 | 2026-09-30 | This full market release is expected to accelerate Abbott's growth trajectory and help the company outperform the market and recapture share in the electrophysiology segment. | Ticker | ABT (ticker) | ABT_e32745b9 | 2026-07-16 | earnings_transcript | ||||||||||||||
| Launch of Guardant Reveal Ultra, the tumor-informed MRD/therapy monitoring test, expected to ship this year. | in 2026 | 2026-01-01 | 2026-12-31 | Could drive higher oncology volumes and strengthen Guardant360/Reveal synergy, improving growth prospects and competitive moat. | Ticker | GH (ticker) | GH_551c816d | 2026-02-19 | earnings_transcript | ||||||||||||||
| Guardant360 Liquid CDx launch following FDA approval. | pending FDA approval; timing to be determined (2026 or later) | 2026-01-01 | 2027-12-31 | Adds a concurrent CDx option, potentially expanding addressable market and cross-sell; regulatory milestone risk. | Ticker | GH (ticker) | GH_a329742a | 2026-02-19 | earnings_transcript | ||||||||||||||
| AstraZeneca SERENA-6 trial results; potential to drive ESR1 monitoring adoption and Guardant360 volumes if positive. | 2026–2027 timeframe | 2026-07-01 | 2027-12-31 | Positive SERENA-6 results could accelerate therapy-monitoring use and overall Guardant360 demand; risk to sentiment if results are negative. | Ticker | GH (ticker) | GH_4e822abd | 2026-02-19 | earnings_transcript | ||||||||||||||
| ACS guideline inclusion for Shield; near-term potential to expand payer coverage and physician adoption. | near term (2026) | 2026-01-01 | 2026-12-31 | Could drive Shield volumes and broaden market access, supporting volume growth. | Ticker | GH (ticker) | GH_17aaaacc | 2026-02-19 | earnings_transcript | ||||||||||||||
| Completion of the acquisition of select outreach laboratory services across Indiana and Northwest Ohio from Parkview Health. | in the very near future | 2026-07-24 | 2026-10-24 | This acquisition will expand Labcorp's patient and provider networks, increase access to its broad test portfolio, and drive volume growth for the Diagnostics business, positively impacting revenue and competitive position. | Ticker | LH (ticker) | LH_e2f765c4 | 2026-04-30 | earnings_transcript | ||||||||||||||
| Initial launch of Precise MRD for colorectal and renal cancers to a select set of customers. | into Q3 | 2026-07-01 | 2026-09-30 | This accelerated launch reflects strong customer interest and allows Myriad to gain early insights into commercialization across multiple indications, potentially expanding its market opportunity. | Ticker | MYGN (ticker) | MYGN_c65d39f3 | 2026-05-05 | earnings_transcript | ||||||||||||||
| Completion of a multi-million dollar multimodal model in Alzheimer's disease. | middle of this year | 2026-07-01 | 2026-08-31 | This represents a significant win in expanding Tempus's data business into new disease areas beyond oncology, demonstrating the broader applicability and monetization potential of their data platform. | Ticker | TEM (ticker) | TEM_8da9f10b | 2026-05-05 | earnings_transcript | ||||||||||||||
| Completion of the migration of Tempus's xT CDx testing volume to the FDA-approved version. | by the end of 2026 to be exiting with the vast majority of volume on that FDA-approved version | 2026-01-01 | 2026-12-31 | This migration is the biggest driver of the expected $500+ ASP upside, directly impacting gross margins and revenue per test. Bullish if completed as planned, bearish if delayed. | Ticker | TEM (ticker) | TEM_30f7dd10 | 2026-02-24 | earnings_transcript | ||||||||||||||
| FDA approval of Tempus's xF liquid biopsy assay, which has been submitted to the FDA. | unlikely to have much of a '26 impact from ASP, but as we get into '27, we'll start to contribute | 2026-01-01 | 2026-12-31 | FDA approval is a prerequisite for ADLT status and broader reimbursement, expected to significantly increase ASPs and contribute to revenue starting in 2027. Bullish if approved, bearish if rejected or delayed. | Ticker | TEM (ticker) | TEM_cfd0d81c | 2026-02-24 | earnings_transcript | ||||||||||||||
| Launch of Tempus's second-generation tumor-naive MRD assay. | at some point, we'll have a really nice assay market | 2026-07-01 | 2027-12-31 | This new assay aims to offer improved performance and compete more effectively in subtypes where tissue is sparse, potentially expanding market reach and driving volume. Bullish if launched with strong performance, bearish if further delays or poor performance. | Ticker | TEM (ticker) | TEM_0bbe29e3 | 2026-02-24 | earnings_transcript | ||||||||||||||
| Launch of Tempus's whole genome heme offering. | goes live this year | 2026-01-01 | 2026-12-31 | This expands Tempus's diagnostic portfolio, potentially attracting new customers and increasing revenue from the heme oncology market. Bullish if launched successfully and gains traction. | Ticker | TEM (ticker) | TEM_a4910b39 | 2026-02-24 | earnings_transcript | ||||||||||||||
| Medicare reimbursement expansion for continuous glucose monitoring (CGM) for Type 2 non-insulin users in the US. | could happen in the fall | 2026-09-01 | 2026-11-30 | This represents a multibillion-dollar opportunity, unlocking coverage for approximately 10 million Medicare beneficiaries and accelerating commercial insurance adoption, which is expected to significantly boost CGM sales. | Ticker | ABT (ticker) | ABT_ba778762 | 2026-07-16 | earnings_transcript | ||||||||||||||
| International rollout of Libre Duo, the world's first dual glucose ketone monitoring sensor. | in the fall | 2026-09-01 | 2026-11-30 | The introduction of this innovative new technology internationally is expected to contribute to the growth and leadership of Abbott's diabetes care business. | Ticker | ABT (ticker) | ABT_6009f906 | 2026-07-16 | earnings_transcript | ||||||||||||||
| Labcorp Investor Day in New York City. | September 10 | 2026-09-10 | 2026-09-10 | Management will share more details about their strategy, which could provide insights into future growth drivers, capital allocation, and operational improvements, potentially impacting investor sentiment and stock valuation. | Ticker | LH (ticker) | LH_538b9123 | 2026-04-30 | earnings_transcript | ||||||||||||||
| FDA approval of GRAIL's Galleri Multi-Cancer Early Detection test following its Premarket Approval (PMA) application. | Q4 2026 - Q1 2027 | 2026-10-01 | 2027-03-31 | FDA approval for Galleri would provide critical regulatory validation for a leading multi-cancer early detection test, de-risking the technology and paving the way for broader commercialization, payer coverage, and physician adoption, impacting the entire MCED segment. | Theme | theme_composer | GRAL, ILMN, LH, DGX | 4 | 0.0002 | 1.18 | 0.92 | Regulatory/Policy | 1.35 | 0.0271 | 2026-07-18 | False | 1 | 0.6014 | 88.1411 | Theme composer | |||
| FDA approval for the new Amulet 360 left atrial appendage device. | potential to be able to get this approved by year end | 2026-10-01 | 2026-12-31 | This approval enables a significant relaunch of a superior product in the $2 billion LAA closure market, positioning Abbott for substantial market share capture in the electrophysiology business. | Ticker | ABT (ticker) | ABT_30e24e43 | 2026-07-16 | earnings_transcript | ||||||||||||||
| CMS granting of Advanced Diagnostic Laboratory Test (ADLT) status for Tempus's xF liquid biopsy assay. | as we get into '27, we'll start to contribute | 2026-10-01 | 2027-03-31 | ADLT status is crucial for securing favorable and consistent reimbursement, leading to a significant ASP lift and closing the reimbursement gap with competitors. Bullish if granted, bearish if delayed or denied. | Ticker | TEM (ticker) | TEM_b3d020d3 | 2026-02-24 | earnings_transcript | ||||||||||||||
| Launch of a state-of-the-art lab in Southeast Michigan as part of the joint venture with Corewell Health. | early next year | 2027-01-01 | 2027-03-31 | This joint venture is a significant growth driver for Quest's hospital channel, contributing to volume growth and expanding collaborative lab solutions. | Ticker | DGX (ticker) | DGX_ae4871f6 | 2026-04-21 | earnings_transcript | ||||||||||||||
| Initial Medicare coverage decisions for FDA-approved Multi-Cancer Early Detection (MCED) tests under the recently passed MCED Act. | H2 2027 - H1 2028 | 2027-07-01 | 2028-06-30 | The MCED Act, signed into law in February 2026, establishes a Medicare coverage pathway for FDA-approved MCED tests, with coverage for beneficiaries phased in starting as early as January 1, 2028. Initial coverage decisions will be crucial for unlocking a massive market for population-level screening. | Theme | theme_composer | GRAL, EXAS, GH, PSNL, LH, DGX, ILMN | 7 | 0.0003 | 1.18 | 0.92 | Regulatory/Policy | 1.35 | 0.0417 | 2026-07-18 | False | 1 | 1.2022 | 176.1867 | Theme composer |
NotesEarnings Summary
| Date | Type | Comment | Detail | Sentiment | Tickers |
|---|---|---|---|---|---|
| 2026-07-19 | Theme Update | Tempus AI and Guardant Health's strong Q1 2026 results validate the Diagnostics & Early Detection theme. TEM's 35% diagnostic growth and GH's 48% revenue surge, driven by liquid biopsies, MRD, and early screening (Shield), underscore robust adoption and technological advancements. Both companies are expanding market reach via AI and commercial partnerships. While reimbursement hurdles for MRD and ASP pressures for screening persist, continuous innovation and strategic execution reinforce the theme's positive outlook. | Earnings Summary | Positive | TEM, GH |
Constituents
- — Castle Biosciences, Inc.
- ABTT2— Abbott Laboratories
- DGXT2— Quest Diagnostics Incorporated
- GHT2— Guardant Health, Inc.
- ILMNT2— Illumina, Inc.
- LHT2— Labcorp Holdings Inc.
- MYGNT2— Myriad Genetics, Inc.
- NEOT2— NeoGenomics, Inc.
- TEMT2— Tempus AI, Inc.
- BDXT2· no notes yet
- EXAST2· no notes yet
- GRALT2· no notes yet
- NTRAT2· no notes yet
- PSNLT2· no notes yet
- QGENT2· no notes yet
- VACYT2· no notes yet